Nucleoside analogs in cutaneous T cell lymphoma.
| Drug/Author . | No. of Patients . | Regimen . | Response Rate (%) . | CR (%) . | Comments . |
|---|---|---|---|---|---|
| Abbreviations: SWOG, Southwest Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; SS, Sezary syndrome; MF, mycosis fungoides; PTCL, peripheral T cell lymphoma; CR, complete response; PR, partial response | |||||
| Fludarabine | |||||
| Von Hoff61 | 31 | 25 mg/m2/d x 5 | 19 | 3 | SWOG: 30% response in good risk |
| 2′-deoxycoformycin | |||||
| Ho62 | 44 | 4 mg/m2 q week x 3, then q 2 wk x 3, q mo x4 | 36 | 2 | EORTC: median response 4.5 mo for SS and 8.3 mo for MF |
| Kurzrock63 | 24 | 3.75-5.0 mg/m2/d q d X 3d q 3 wks | 71 | 25 | Median response was 2 mo in tumor stage MF and 3.5 mo in SS. Three pts with PTCL responded. |
| 2-CdA | |||||
| Saven64 | 15 | 0.05-0.15 mg/kg/d x 7 d | 47 | 20 | Median response of 5 mo |
| Kuzel65 | 21 | 0.1 mg/kg/d x 7 d or x 5 d | 28 | 14 | Median response 4.5 mo for CR, 2 mo for PR |
| Gemcitabine | |||||
| Zinzani66 | 44 | 1.2 gm/m2 d 1,8,15 q mo x 3 cycles | 70 | 11.5 | No difference in response between PTCL (N=14) and MF; median response 15 mo for CR, 10 mo for PR |
| Drug/Author . | No. of Patients . | Regimen . | Response Rate (%) . | CR (%) . | Comments . |
|---|---|---|---|---|---|
| Abbreviations: SWOG, Southwest Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; SS, Sezary syndrome; MF, mycosis fungoides; PTCL, peripheral T cell lymphoma; CR, complete response; PR, partial response | |||||
| Fludarabine | |||||
| Von Hoff61 | 31 | 25 mg/m2/d x 5 | 19 | 3 | SWOG: 30% response in good risk |
| 2′-deoxycoformycin | |||||
| Ho62 | 44 | 4 mg/m2 q week x 3, then q 2 wk x 3, q mo x4 | 36 | 2 | EORTC: median response 4.5 mo for SS and 8.3 mo for MF |
| Kurzrock63 | 24 | 3.75-5.0 mg/m2/d q d X 3d q 3 wks | 71 | 25 | Median response was 2 mo in tumor stage MF and 3.5 mo in SS. Three pts with PTCL responded. |
| 2-CdA | |||||
| Saven64 | 15 | 0.05-0.15 mg/kg/d x 7 d | 47 | 20 | Median response of 5 mo |
| Kuzel65 | 21 | 0.1 mg/kg/d x 7 d or x 5 d | 28 | 14 | Median response 4.5 mo for CR, 2 mo for PR |
| Gemcitabine | |||||
| Zinzani66 | 44 | 1.2 gm/m2 d 1,8,15 q mo x 3 cycles | 70 | 11.5 | No difference in response between PTCL (N=14) and MF; median response 15 mo for CR, 10 mo for PR |